Martinez Bueno A, Molina MA, Fielding A, et al. Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. ESMO 2017, abstract LBA42.
CD44 en MET, partners in carcinogenese van CRC
okt 2021 | Maag-darm-leveroncologie